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Abstract 
Background and Objective: Hepatocellular carcinoma (HCC) is the most common primary liver 
malignancy, and its current management relies heavily on locoregional therapy for curative therapy, 
bridge to transplant, and palliative therapy. Locoregional therapies include ablation and hepatic 
artery directed therapies such as embolization and radioembolization. In this study we evaluate the 
feasibility of using novel antivascular ultrasound (AVUS) as a noninvasive locoregional therapy to 
reduce perfusion in HCC lesions in a rat model and monitor the effect with contrast-enhanced 
ultrasound imaging. 
Methods: HCC was induced in 36 Wistar rats by the ingestion of 0.01% diethylnitrosamine (DEN) 
for 12 weeks. Two therapy regimens of AVUS were evaluated. A primary regimen (n = 19) utilized 
2 W/cm2, 3 MHz ultrasound (US) for 6 minutes insonation with 0.7 ml of microbubbles administered 
as an intravenous bolus. An alternate dose at half the primary intensity, sonication time, and contrast 
concentration was evaluated in 11 rats to assess the efficacy of a reduced dose. A control group (n 
= 6) received a sham therapy. Tumor perfusion was measured before and after AVUS with 
non-linear contrast ultrasound (NLC) and power Doppler (PD). The quantitative perfusion 
measures included perfusion index (PI), peak enhancement (PE), time to peak (TTP), and perfusion 
area from NLC and PD scans. Total tumor area perfused during the scan was measured by a 
postprocessing algorithm termed delta projection. Tumor histology was evaluated for signs of tissue 
injury and for vascular changes using CD31 immunohistochemistry. 
Results: DEN exposure induced autochthonous hepatocellular carcinoma lesions in all rats.  
Across all groups prior to therapy, there were no significant differences in the nonlinear contrast 
observations of peak enhancement and perfusion index. In the control group, there were no 
significant differences in any of the parameters after sham treatment.  After the primary AVUS 
regimen tested, there were significant changes in all parameters (p ≤ 0.05) indicating substantial 
decreases in tumor perfusion. Peak enhancement in nonlinear contrast scans showed a 37.9% ± 
10.05% decrease in tumor perfusion. Following reduced dose AVUS, there were no significant 
changes in perfusion parameters, although there was a trend for the nonlinear contrast observations 
of peak enhancement and perfusion index to increase.  
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Conclusion: This study translated low intensity AVUS therapy into a realistic in vivo model of HCC 
and evaluated its effects on the tumor vasculature. The primary dose of AVUS tested resulted in 
significant vascular disruption and a corresponding reduction in tumor perfusion. A reduced dose of 
AVUS, on the other hand, was ineffective at disrupting perfusion but demonstrated the potential for 
enhancing tumor blood flow. Theranostic ultrasound, where acoustic energy and microbubbles are 
used to monitor the tumor neovasculature as well as disrupt the vasculature and treat lesions, could 
serve as a potent tool for delivering noninvasive, locoregional therapy for hepatocellular carcinoma. 
Key words: Hepatocellular carcinoma, non-invasive cancer therapies, anti-vascular ultrasound, preclinical 
studies 
Introduction 
Hepatocellular carcinoma (HCC) is the most 
common primary liver malignancy and the third 
leading cause of cancer-related death worldwide [1]. 
In the United States, two-year survival times have 
been reported at < 50% [2, 3]. At present, curative 
therapies for very early and early stage HCC include 
thermal ablation, resection, and liver transplantation 
[4, 5] However, tumors may be beyond criteria for 
these interventions, often resulting in management of 
intermediate, advanced, and terminal stage HCC 
patients with transarterial embolization, 
radioembolization, or systemic chemotherapy for 
palliative treatment [6].  Hence, nonsurgical 
locoregional therapies including ablation, 
transarterial embolization, and radioembolization 
through interventional oncology play a central role in 
curative therapy, as a bridge to transplantation, and 
as palliative treatment of HCC [7-9]. Here, we study 
the application of antivascular ultrasound as a 
locoregional therapy for HCC, which in addition to 
requiring a less extensive and less expensive 
infrastructure to employ, utilizes a theranostic 
microbubble platform and is noninvasive. 
Antivascular ultrasound (AVUS) therapy is a 
technique that uses low-intensity, unfocused 
ultrasound in combination with intravenously 
administered microbubbles to disrupt the tumor 
neovasculature [10–15]. Microbubbles, commonly 
used as ultrasound contrast agents, consist of a lipid, 
polymer, or protein shell and a gas core. At 1-10 µm in 
diameter, they are small enough to pass through the 
lumina of capillaries yet large enough to prevent 
extravasation from vessels, ensuring their 
intravascular location [16–18]. In AVUS, microbubbles 
are administered intravenously, and then ultrasound 
is applied to the tumor, stimulating the circulating 
microbubbles in the tumor vasculature. This causes 
the bubbles to oscillate at their resonance frequency 
(stable cavitation) or collapse (inertial cavitation), 
generating heat, shear stress, and microstreaming 
around the bubbles [19, 20]. The slow blood flow of 
the disorganized tumor vasculature exposes the 
tumor endothelium to each microbubble for a longer 
residence time compared to the surrounding healthy 
vasculature, where the microbubbles pass more 
quickly. The microbubbles’ localized bioeffects 
damage the adjacent endothelial cells and destroy the 
tumor’s vascular supply, leading to ischemia and 
necrosis of neoplastic cells [21, 10, 13, 15] Rather than 
affecting tumor cells directly, the aim of AVUS is to 
destroy the tumor vasculature. This is analogous to 
pharmacologic vascular disrupting agents (VDAs) 
such as combretastatin, which target the tumor 
vasculature to cause ischemia and resultant necrosis 
of the tumor cells, inhibiting tumor growth and 
leading to regression of the tumor [23].  
The effect of AVUS on tumor perfusion may be 
assessed by contrast-enhanced ultrasound (CEUS). 
CEUS employs microbubbles as contrast agents with 
shorter ultrasound pulses. Two CEUS modes of 
interest are nonlinear contrast and power Doppler 
modes. Nonlinear contrast ultrasound detects blood 
perfusion by detecting the nonlinear harmonic and 
subharmonic frequencies created by circulating 
microbubbles. This provides a high contrast-to-tissue 
ratio of tissue perfusion because biological tissue does 
not emit subharmonic frequencies [24, 25]. 
Additionally, this allows detection of perfusion at 
greater tissue depths due to reduced attenuation of 
the lower frequency subharmonics [26, 27]. Power 
Doppler ultrasound detects the strength of the 
Doppler signal scattered by blood cells and 
microbubbles, and the signal is sensitive to low 
velocity blood flow in small diameter vessels 
(capillaries) [28, 29]. 
This study evaluates the theranostic ability of 
ultrasound and microbubbles in AVUS to disrupt and 
image tumor perfusion when translated into a more 
complex and realistic rat model of HCC. Two levels of 
tumor insonation were evaluated. One dose was 
translated from the dose successfully used in previous 
murine cancer studies, taking into consideration the 
larger size and blood volume of rats versus mice. 
Another reduced dose was used to determine whether 
AVUS was still effective while minimizing the 
ultrasound exposure to subjects.  
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Materials and Methods 
Animal Model 
The University Institutional Animal Care and 
Use Committee approved all animal protocols.  
Thirty-six Wistar rats (Charles River Laboratories, 
Wilmington, MA, USA) weighing between 300-400g 
were acquired and kept under controlled 
environmental conditions (25°C and a 12 h light/dark 
cycle).  After one week of acclimation, the rats were 
initiated on 0.01% diethylnitrosamine (DEN, Sigma 
Aldrich, St. Louis, MO, USA) in their drinking water, 
which they ingested ad libitum for 12 weeks.  DEN 
was replaced 1-2 times per week as necessary, and 
rats were weighed twice weekly. Normal drinking 
water was returned at the beginning of the 13th week. 
For the sonographic procedures, the rat was placed in 
a non-rebreathing gaseous anesthetic system 
[VetEquip Inc, Livermore, CA, USA] and general 
anesthesia was induced with 4% isoflurane (IsoSol; 
VEDCO Inc, St Joseph, MO). A nose cone was taped in 
place, anesthesia was maintained with 1-3% 
isoflurane and 1.5–2.0 L.min-1 oxygen, and a tail vein 
26G catheter [Covidien, Dublin, Ireland] was inserted. 
Animals were positioned supine on a heated bed 
(VisualSonics Vevo imaging station, Fujifilm, Toronto, 
Canada), the abdomen was depilated, and continuous 
vital signs including body temperature, heart rate, 
and respiratory rate were recorded. At the completion 
of each study, the rats were euthanized by carbon 
dioxide asphyxiation, and necropsy was performed.  
Antivascular Ultrasound Therapy 
The rats were monitored for the development of 
tumors using gray scale ultrasound (VisualSonics 
VevoLAZR, Fujifilm, Toronto, Canada) beginning 11 
weeks into the DEN diet and weekly thereafter. 
During monitoring sessions, diagnostic scans were 
performed identifying and measuring visualized 
lesions. A single tumor most suitable for AVUS 
therapy was selected from the often multiple tumors 
developed in the liver based on the tumor location 
(ventral and accessible to ultrasound imaging and 
therapy), size (6 – 14 mm diameter), 
hyperenhancement with microbubble administration, 
and minimal cystic or hemorrhagic changes as 
identified in the ultrasound images. After selecting 
and clearly identifying the tumor, the diagnostic 
transducer was secured in an adjustable mount 
(VisualSonics Vevo imaging station, Fujifilm, Toronto, 
Canada) to maintain a fixed position over the tumor. 
The same mount was used to position the low 
intensity ultrasound therapy probe (Dynatronics 
D150 Plus, Dynatronics Salt Lake City, UT) to ensure 
the therapy beam’s accurate alignment with the 
imaged HCC.  
Two AVUS therapy regimens were used. A 
primary dose was selected based on our previous 
studies in mice [10, 12, 30] taking into account the 
greater body weight and blood volume of the rats. 
This primary regimen (n=19) utilized 2.0 W/cm2; 3 
MHz for a total of 6 minutes insonation [3 x 2 min 
insonations each separated by 2 min]). 0.5 mL 
perflutren microbubbles (Definity, Lantheus, N. 
Billerica, MA, USA) were injected as a bolus via the 
tail vein catheter prior to the first insonation and 0.2 
mL prior to the second insonation; fractionating the 
microbubble administration ensured that 
microbubbles remained in circulation throughout the 
therapy. In the reduced dose regimen (n=11) 1.0 
W/cm2, 3 MHz was applied for a total of 3 minutes 
insonation [3 x 1 min insonations each separated by 1 
min]), 0.1 mL microbubbles were injected before each 
insonation. A control group (n=6) received a sham 
therapy in which the microbubbles were replaced 
with 0.7mL normal saline, and the US machine was 
not switched on.  
Multimodal ultrasound evaluation of HCC 
perfusion 
B-mode ultrasound images (VisualSonics, 
VevoLAZR, 21 MHz linear transducer, Fujifilm, 
Toronto, Canada) of each HCC were acquired prior to 
therapy to assess the tumor size and positioning; the 
imaging was repeated after AVUS.  This same 
equipment was used to acquire contrast-enhanced 
ultrasound (CEUS) scans to assess tumor perfusion 
before and after AVUS; fixed imaging parameters 
were used (18 MHz; contrast gain = 41; 2D gain = 18; 
sensitivity = 3; standard line density; power = 4). An 
intravenous bolus injection of  up to 0.1 mL 
microbubbles  was given for each of the  CEUS studies 
and power Doppler (PD) observations were recorded 
and analysed (16 MHz; frame rate = 4-6; Doppler gain 
=37 dB; 2D gain = 18 dB; sensitivity = 3; standard line 
density; high,  power = 100%; persistence = medium).  
Tumor perfusion was assessed on complete 
CEUS data sets. In the nonlinear contrast scans (NLC), 
analyses utilized imaging software (VevoLab, 
Fujifilm, VisualSonics, Toronto, Canada). The borders 
of each tumor, were manually outlined in the initial 
B-mode image to create a region of interest (ROI). The 
mean intensity of the ROI was fitted to a bolus 
perfusion model [27], and the following parameters 
were assessed: peak enhancement (PE - the difference 
between the maximum amplitude and baseline 
intensity, which is proportional to microbubble 
concentration and indicative of relative blood 
volume); perfusion index (PI - the area under curve 
divided by mean transit time of flow); and time to 
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peak (TTP - time from contrast administration to peak 
enhancement).   
The PD scans were analyzed using a previously 
described IDL-based platform for vascular analysis 
[31]. Tumor vascularity was measured within the 
tumor ROI and the Doppler image’s color scale was 
used to detect pixels with flow (colored pixels) and 
the strength of Doppler signal (color bar). These were 
used to calculate area-based measurements and color 
weighted fractional area (CWFA), representing 
contrast flow through the region over time. This 
allowed dynamic assessment of the tumor area 
perfused as well as flow changes in the perfused 
vessels.  
The total tumor area perfused during the scan 
was measured by a postprocessing subtraction 
algorithm, the delta projection, that is applied to 
greyscale images to assess contrast changes [32]. By 
tracking the running maximum intensity in each pixel 
following the injection of microbubbles and 
subtracting the sequence’s baseline intensity, the 
echogenic increases related to the flow of contrast are 
detected; thus, there is a global assessment of the 
proportion of the tumor being perfused.  
Histopathologic Studies 
At necropsy, tissue from the treated HCC and 
the adjacent normal liver were harvested for 
histologic examination. The tissues were preserved in 
10% neutral buffered formalin followed by 70% 
ethanol and embedded in paraffin for sectioning. The 
institutional veterinary comparative pathology core 
prepared H&E sections and CD31 
immunohistochemistry (AB28364; Abcam, 
Cambridge, MA) identifying the vascular 
endothelium.10x magnified images of the tumor were 
stitched together (ZEN software, Carl Zeiss 
Microscopy, Oberkochen, Germany) to produce 
images of the entire tumor. Areas of hemorrhage and 
necrosis were segmented and analyzed in ImageJ [33] 
and recorded as the percentage area of histologic 
change.  
 Statistical Analysis 
 One-tailed, paired Student’s t-tests assessing for 
a decrease in tumor perfusion after therapy as 
demonstrated in previous murine studies were used 
to compare pre- and post-AVUS perfusion parameters 
within each treatment group. Additionally, ANOVA 
was used to compare pre-AVUS parameter values 
between groups, ensuring the groups were 
equivalent. ANOVA was used to compare percent 
change of perfusion parameters between the three 
treatment arms. One-tailed Student’s t-tests were used 
to evaluate histologic changes, assuming vessels 
would dilate or expand with therapy and that therapy 
would increase tumor necrosis and hemorrhage 
relative to primary or sham tumors as shown in 
previous studies. An alpha of 0.05 was considered 
statistically significant. Values are reported as mean ± 
SEM. Statistics were calculated using Stata version 
15.0, StataCorp, College Station, TX. 
Results 
Animal model monitoring 
The initial weight of animals on acquisition was 
364.2g ± 33.5 (range 347-379g). The rate of weight gain 
reduced with exposure to DEN, and rats reached a 
final weight of 447g ± 80 at the time of therapy.  All 
animals developed liver disease and multiple foci of 
hepatocellular carcinoma (HCC), seen on B-mode 
ultrasound imaging via ascites and echogenic 
changes, gross pathology by nodularity, 
hepatosplenomegaly and multifocal lesions, and by 
histologic analysis confirming HCC diagnosis. The 
treatments ranged from day 88 - 119 from the start of 
the DEN diet (week 13-17).  
Tumors in all treatment groups showed 
similar perfusion prior to therapy. 
Contrast-enhanced US studies showed 
equivalent vascular perfusion kinetics throughout all 
tumors prior to AVUS therapy. By nonlinear contrast 
US imaging, the mean peak enhancement before 
therapy among all rats was 4.88 ± 0.88 a.u. (SEM) with 
no difference between sham, primary dose, and 
reduced dose groups (ANOVA F2,33=0.17, p=0.85). The 
tumors also had equivalent pre-therapy rates of 
perfusion, modeled by perfusion index (PI): 4.24 ± 
0.81 a.u. among all 39 tumors (F2,33=0.14, p=0.14).  
The primary AVUS dose shows reduced tumor 
perfusion after therapy, quantitated via NLC 
perfusion parameters. 
Nonlinear contrast perfusion parameters 
showed a decrease in tumor perfusion after treatment 
with AVUS at the primary dose. An example can be 
appreciated visually in Figure 1 by the decreased 
enhancement of the post-treatment image of the 
primary dose (Figure 1d) versus an example of a sham 
treatment in Figure 1a, which shows equivalent pre 
and post enhancement. Additionally, the examples of 
pre and post time intensity curves (Figure 1f) 
demonstrate the lower peak enhancement after 
therapy that quantitates this decrease.  
This decrease in enhancement was evident in the 
primary dose arm. NLC peak enhancement, 
representing relative blood volume perfusing the 
tumor, decreased by >35% in 14 of 19 cases, as 
demonstrated in Figure 2b. Four rats showed no 
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response, and one increased slightly. The average 
peak enhancement of the group fell from 5.30 ± 1.28 
a.u. before therapy to 2.77 ± 0.65 a.u. after therapy 
(paired t-test p=0.003). The average decrease between 
pre and post PE was 37.9% ± 10.05% within each 
tumor. In comparison, four of six sham-treated 
tumors showed no response to therapy (stayed flat 
with less than 10% change in Figure 2a). The group’s 
average peak enhancement remained constant at 3.87 
± 2.41 a.u. before and 3.07 ± 1.64 a.u., after therapy (p 
= 0.17), decreasing only 8.8% ± 6.8% within each 
tumor (p = 0.02 versus primary dose).  
The primary dose group’s reduction in NLC 
peak enhancement was accompanied by a decrease in 
the rate of perfusion. The perfusion index (PI) 
decreased in 12 of the 19 rats (Figure 2e). The group’s 
PI decreased from 4.65 ± 1.20 a.u. before therapy to 
2.81 ± 0.65 a.u. after therapy (p = 0.007), and was 
accompanied by a lengthened time to peak 
enhancement (TTP), which slowed from 16.5 ± 1.8 
seconds to 24.6 ± 1.8 sec (p=0.009). In comparison, the 
sham group showed no significant change in pre- and 
post-therapy PI or TTP (p = 0.20, p = 0.07) (Figure 2d). 
These parameters show reduction and slowing of 
tumor perfusion following primary dose AVUS.  
Power Doppler and delta projection also show 
reduced perfusion after the primary AVUS 
dose: reduced area of perfusion and a weaker 
intensity of contrast within perfused vessels is 
observed.  
Similarly, power Doppler showed a reduction in 
perfusion kinetics after primary AVUS dose. The peak 
perfused area (PPA) decreased from 87.2 ± 3.6 a.u. to 
76.4 ± 9.1 a.u. as a group (p = 0.014). Assessing the 
change within this decreased area using the color 
weighting of the Doppler signal’s strength (color 
weighted flow area, CWFA), CWFA PE decreased 
from 48.0 ± 3.0 a.u. to 35.5 ±3.6 a.u. (p = 0.007), 
indicating weaker flow within the smaller perfused 
area. The sham group remained constant for these 
parameters (SI Table S1).  
Delta projection post-processing, measuring 
total tumor area receiving any perfusion throughout 
the scan, showed that less of the tumor area was 
perfused after therapy. Whereas 75.7% ± 4.2% area of 
primary dose tumors enhanced before therapy, only 
59.1 ± 6.4% enhanced after therapy (p = 0.002). 
Primary dose stayed constant at 57.6% ± 10.0% before 
and 58.2% ± 10.2% area perfused after therapy (p = 
0.63). 
Reduced dose AVUS showed increased 
perfusion but inconsistently.   
Though reduced dose AVUS showed a net 
increase in perfusion as a group, this increase was 
variable between cases and was not statistically 
significant. NLC peak enhancement showed 7 cases 
 
 
Figure 1 Nonlinear Contrast and Power Doppler Images Pre- and Post-AVUS. The top row of images shows maximum intensity projection images from nonlinear 
contrast scans with the tumor region of interest indicated. The sham treatments show equivalent perfusion before and after therapy. A notable decrease in tumor contrast 
enhancement can be noted in the Post image of primary dose therapy. Reduced-dose therapy, while showing a variable response overall, showed an increase in the majority (7 
of 11 cases) that is shown above by the increase in contrast intensity. Power Doppler images demonstrate similar findings, with equivalent perfusion area and intensity before and 
after therapy in sham treatment, decrease in primary dose AVUS, and increase of Doppler signal in reduced dose. Contrast enhancement curves show examples of each therapy 
arm before and after treatment. Equivalent peak enhancement levels are seen in the sham treatment, while primary dose peak enhancement and total contrast delivered 
decreases, and reduced dose therapy shows a slightly higher peak enhancement with continuing contrast recirculation within the tumor.  
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increased, 3 cases decreased, and 1 case remained 
constant in perfusion (Figure 2c). As a group, peak 
enhancement showed rose from 4.71 ± 1.48 a.u. to 4.90 
± 2.72 a.u. (p = 0.90), with a 38.3% ± 26.2% average 
increase in perfusion in individual cases. Perfusion 
index did not change significantly, showing pre and 
post-therapy values of 3.66 ± 1.00 a.u. and 6.65 ± 2.56 
a.u., respectively (p = 0.92). Power Doppler and delta 
projection measures of perfused area showed no 
change from 67.5 ± 9.3 pre to and 68.2 ± 8.5 a.u. post 
therapy, respectively, for PAI (p = 0.23). Delta 
projection showed 66.8% ± 8.2% area perfused before 
and 64.3% ± 7.8% after therapy (p = 0.29). An example 
of these trends of increased strength of perfusion 
within a constant area can be noted in Figure 2g and 
3h. However, this was found to be inconsistent and 
variably evoked.  
The differences between the three arms tested 
are summarized in Figure 3, with the percent changes 
before and after therapy measured in individual 
tumors and then averaged for each group. While 
sham tumors demonstrate <10% change for each 
parameter, the primary AVUS dose consistently 
reduces perfusion parameters. The mean increases 
following reduced dose AVUS indicate a domain of 
therapy that differs significantly from the primary 
dose decreases in perfusion. 
Histologic analysis shows an increased number 
of medium and large-sized vessels in tumors 
following AVUS. 
Endothelial cell staining using anti-CD31 
immunohistochemistry suggested vessel dilation in 
primary dose treated tumors compared to sham 
tumors. Small, narrow diameter blood vessels 
(5-15μm in diameter) comprised the majority of 
vessels in the sham-treated tumors as well as in 
treated tumors. Primary dose tumors showed pools of 
red blood cells (RBCs, * in Figure 4a) with 
endothelium on both sides, suggesting a wide dilation 
of vessels. Additionally, pooled RBCs with 
hemorrhage on only one side (Figure 4e) indicate 
 
Figure 2 Nonlinear Contrast Imaging Changes Pre- and Post- AVUS. Nonlinear contrast (NLC) diagnostic ultrasound enhancement curves were fitted to a bolus 
perfusion model, and perfusion parameters including peak enhancement and perfusion index were used to evaluate changes in perfusion kinetics. Peak enhancement, 
representing blood volume perfusing the tumor, stayed constant before and after sham therapy, whereas it decreased in 14 of 19 cases, showing a change in mean of 5.30 ± 1.28 
a.u. to 2.77 ± 0.65 a.u. in the primary dose arm (p = 0.003). Perfusion index, representing the rate of perfusion over time, also stayed constant in the sham arm but decreased 
in the primary dose arm. A reduced dose of AVUS showed an increase in the majority of cases by mean values, but was not found to be significant nor consistent. 
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rupture and extravasation of RBCs from vessels. 
Measuring and counting vessels allowed further 
understanding of these vascular changes. Counts of 
small vessels were equivalent between treatment 
arms with 684 ± 49 vessels/ six high power fields. 
More medium (16-50 μm) and large (>50 μm) vessels 
were observed in tumors treated with primary dose 
AVUS. On average there were 126 ± 32 medium 
vessels in the treated tumors, compared to 72 ± 12 
medium vessels in the sham. Large vessels were also 
more frequent in treated tumors, with 7.5 ± 3.6 vessels 
counted compared to only 1.9 ± 1.3 vessels in sham 
tumors. These trends of increasing medium (p = 0.06 
primary dose) and large vessels (p = 0.06 primary 
dose, p = 0.06 reduced dose) in treated tumors 
suggests vascular dilation after therapy.  
 
 
Figure 3 Percent Change in Perfusion Parameters. Nonlinear contrast ultrasound showed a decrease in blood volume perfused of 37.9% ± 10.05% in each tumor before 
and after primary dose AVUS, while perfusion only decreased 8.8% ± 6.8% in the sham arm (p = 0.02). Perfusion per tumor in the reduced dose arm increased compared to 
primary dose AVUS (p = 0.02) but was not significant versus the sham arm (p = 0.11). Perfusion index showed a similar pattern, but did not show significant differences versus 
sham treatment. Delta projection, quantifying the tumor area perfused throughout the scan, showed a constant perfusion in sham (increase of 1.2% ± 3.2%) and a decreased area 
of the tumor receiving perfusion with contrast agent after primary dose AVUS (decrease of 22.9% ± 7.3%, p = 0.005). 
 
Figure 4 CD31 Staining of Vascular Changes in AVUS-treated rats. a) i. Small narrow vessels comprising the majority of vessels in sham tumors. ii. A primary dose 
tumor showing increased frequency of larger diameter vessels (solid arrows). iii. Pooling of RBCs (*) with endothelium on both sides, suggesting a wide dilation of a vessel. iv. 
Pooled RBCs (*) with hemorrhage on only one side, indicate possible rupture and extravasation. b) Counts of small, narrow diameter blood vessels (5-15um in diameter), medium 
vessels (16-50um), and large vessels (>50um) were measured throughout the tumor sections. While counts of small vessels were similar between all three treatment arms, a 
trend of increasing counts of medium (p = 0.06 primary dose) and large vessels (p = 0.06 primary, p = 0.06 reduced) in treated tumors were noted, suggesting vascular dilation 
after therapy. 
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Figure 5 Tissue damage over time included increased hemorrhage and necrosis on H&E. Necrosis (a), pools of hemorrhage (b), and diffuse infiltrating hemorrhage 
(c) were observed after immediate sacrifice. Necrosis, hemorrhage, fibrin replacement, and neutrophilic infiltrate (d) were present in a small cohort sacrificed 1-4 days after 
AVUS.  
 
Tumor sections stained with H&E staining were 
analyzed for the percent area of hemorrhage and 
necrosis to investigate damage immediately after 
AVUS. In the sham group, an average of 10% ± 2% 
area of the tumor section showed damage, which was 
statistically equal to the 8% ± 4% and 9% ± 2% of 
damage in reduced and primary dose treated tumors 
sacrificed two hours after AVUS (ANOVA F2,27 = 2.00, 
p = 0.15). The range of damage included necrosis, 
pools of hemorrhage, and hemorrhage infiltrating 
between tumor cells (Figure 5).  
Gross hemorrhage or necrosis was not observed 
in the adjacent liver.  Changes in the adjacent liver 
included single cell necrosis and multiple foci of 
coagulative necrosis, consistent with ischemia 
occurring in cirrhosis, and was present in sham and 
AVUS-treated animals. 
Discussion 
Antivascular ultrasound therapy is a novel 
localized therapy that applies low-intensity 
ultrasound to tumors in combination with 
intravenously-administered circulating microbubbles 
to induce vascular changes [10, 31, 12, 13, 15]. This 
technique has been demonstrated to provide a 
non-invasive means of disrupting the tumor 
vasculature in a subcutaneous murine model of 
melanoma [21, 34, 13, 15], but has not yet been 
investigated as a therapy for HCC. The use of an 
autochthonous model of HCC induced by DEN 
hepatotoxin in this study allows for a realistic 
evaluation of HCC with authentic features in the 
setting of chronic liver disease and cirrhosis [35]. This 
provides a necessary step in translation of treating 
neoplasms in situ with the proper vascular modeling 
for this vascular therapy.  
In this realistically complex model the chemical 
hepatotoxin diethylnitrosamine (DEN) produces 
primary metabolic activation and DNA alkylation, 
leading to hepatic necrosis, inflammation, fibrosis, 
and eventual carcinogenesis that closely mimics 
chronic liver disease and development of HCC in 
humans [36, 37]. Compared to the subcutaneous 
melanoma and colorectal cancer murine models 
previously studied, this provides a more realistic 
environment and recapitulates the unique dual blood 
supply of HCC lesions and the surrounding liver. This 
model also allows for factors that would be 
encountered in treating HCC in humans, such as 
ultrasound attenuation, heat dissipation to 
surrounding tissues and blood vessels, and damage to 
the surrounding liver and organs. 
The primary dose of AVUS studied was able to 
reduce perfusing blood volume in the tumor and rate 
of blood flow. On nonlinear contrast ultrasound 
(NLC) studies immediately after therapy, the primary 
dose showed a reduction in peak enhancement, which 
represents relative blood volume perfusing the tumor, 
with an individual decrease of about 38% ± 10% in 
each tumor. Additionally, blood flow was slower after 
therapy. Time to peak and perfusion index both 
slowed. The decreased rate and intensity of flow 
observed on NLC were confirmed by power Doppler 
measures, including CWFA peak enhancement, which 
revealed that within the reduced area being perfused, 
the volume of blood and contrast being delivered is 
decreased [38, 39]. These independent CEUS 
investigations of blood flow with high contrast to 
tissue ratio support the ability of AVUS to disrupt 
tumor perfusion, in accordance with previous studies. 
It is also close to the 45% ± 6% decrease in perfused 
area previously observed when treating subcutaneous 
murine melanoma with 1 minute of AVUS [10]. In the 
prior study, area perfused was further decreased by 
67% ± 8% with a 3-minute treatment of AVUS at the 
same parameters, indicating the potential for a greater 
effect of AVUS by increasing the time of treatment.  
The variability in the treatment response shown 
in Figure 2 could be a result of multiple factors related 
to tumor biology and experimental protocol. 
Differences in tumor hemodynamics between animals 
could cause variability in the treatment response. For 
example, tumors with faster flow are likely to have 
weaker response to the treatment because of the 
reduced interaction between microbubbles and 
ultrasound due to rapid transit of the microbubbles 
through the ultrasound beam. In our studies, a fixed 
dose of contrast was used in all cases. Variability in 
animal weight and tumor size between individual 
cases was not accounted for and could have 
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contributed to differences in the response. Finally, 
imaging was performed in a fixed 2D plane which is 
unlikely to capture antivascular response in all parts 
of the tumor and may cause variability in the 
measured treatment response. The recent advances in 
3D imaging [40] could potentially overcome the 
current limitations of 2D imaging. 
Considering the perfusion changes together with 
histological findings of vascular enlargement support 
an effect on the tumor vasculature ranging from 
dilation to hemorrhage. The early sacrifice timepoint 
in this study allowed a closer understanding of the 
immediate mechanism of AVUS as opposed to the 
subsequent bioeffects of ischemia, hypoxia, and 
necrosis that have been previously noted [21, 10]. 
Similar to the observations of Bunte et al [21] showing 
more prominent vessels and dilation on H&E, the 
CD31 immunohistochemistry in this study allowed 
measurement of vascular diameter and identification 
of dilated and ruptured blood vessels and pools of 
hemorrhage that were not enclosed by endothelium. 
The increased incidence of medium- and 
large-diameter vessels in tumors treated with primary 
dose AVUS points toward dilation and impaired 
integrity or rupture that can lead to hemorrhage.  
These findings support the efficacy of AVUS as a 
physical antivascular therapy for HCC in the context 
of its authentic anatomical location, 
microenvironment, and blood supply. The proven 
perfusional effect of AVUS after translating from a 
subcutaneous model to an autochthonous model 
addresses concerns about ultrasound attenuation in 
treating tumors within visceral organs versus 
subcutaneous tumors and takes into account the 
authentic tumor vasculature. The spatial confinement 
of the ultrasound beam to the tumor without targeting 
surrounding liver, which should have preserved 
perfusion, was also assessed. In this study, deleterious 
effects beyond those due to cirrhosis were not 
observed in the surrounding liver. However, the 
timepoint investigated does not preclude the 
development of necrosis over time.   
Unexpectedly, a nonlinear dose effect was seen 
when evaluating a reduced dose of AVUS. Contrary 
to the milder disruptive effect that was expected, the 
reduced dose showed a variable effect, with 
enhancement of flow in the majority of cases. The 
average increase of 38% ± 26% may be attributed to 
tissue heating induced at the lower intensity of 
ultrasound and decreased concentration of 
microbubbles. The use of low-intensity ultrasound in 
the absence of microbubbles as in physical therapy 
has been demonstrated to cause increases in muscle 
perfusion as early as 1955, in a study demonstrating 
an increase in blood flow after insonation with 1.0 
W/cm2 US for 15 minutes [41]. Thus, with the 
reduced intensity, it is possible that hyperthermic 
effects involving increased flow dominates in this 
regimen compared to the higher intensity’s 
predominantly disruptive effects associated with 
stronger thermal and mechanical forces on the 
vascular endothelium.  
The effects of AVUS observed in this study are 
influenced by both the concentration of microbubbles 
and ultrasound parameters. An increased 
microbubble concentration provides more 
sonosensitizers to affect the vasculature. Additionally, 
with higher concentrations, microbubbles are more 
tightly packed, placing more bubbles in closer 
proximity to the tumor’s endothelial cells. Previous 
studies have shown that the effects of microbubbles 
extend immediately around the microbubbles. 
Therefore, better approximation of the bubbles to the 
endothelium could enhance the therapeutic effect. 
Secondly, the intensity of US used causes greater 
amplitudes of bubble oscillation, generating higher 
shear and heating by heat viscous damping of the 
bubble oscillations.  
In addition to antivascular ultrasound targeting 
tumor microvasculature, contrast-enhanced 
ultrasound enables imaging of tumor vasculature 
with high sensitivity and specificity. This 
ultrasound-microbubble combination provides a 
unique theranostic platform where externally 
triggered treatment and monitoring can be performed 
serially by simply changing the mode of ultrasound 
operation. The use of remotely triggered theranostics 
allow for early recognition of the disease and the 
controlled, image-guided treatment [42]. Although 
the focus of this study was to use a predetermined 
AVUS treatment, it is reasonable to anticipate 
contrast-enhanced imaging to guide the treatment, 
where the dose is adjusted based on the changes in 
tumor vasculature observed following treatment. The 
recent approval of microbubble contrast agent for 
hepatic imaging in the US and the well-established 
role of microbubbles in clinical imaging in many 
countries around the world furthers the potential of 
translation of the study to human subjects.  
Additionally, AVUS’ use of microbubbles that 
can be customized provides a platform for further 
development to improve localized drug delivery, 
tumor targeting, and imaging. It is well known that 
the leaky tumor vasculature is a limiting factor for the 
therapeutic response via the extravasation of drugs 
from hypopermeable tumor vessels. The use of AVUS 
can safely and possibly reversibly increase the 
permeability of the tumor vessel walls and 
temporarily enhance the accumulation of anticancer 
drugs [43]. Furthermore, the microbubbles may be 
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loaded with drug cargo or conjugated with drug 
nanoparticles or liposomes. Encapsulating cargo that 
is unstable or easily degraded in the plasma could 
protect antibodies, RNA, or DNA [44]. Bursting 
loaded MBs within the tumor would allow local 
release while sparing tissues outside the US beam, 
and could increase the permeability and uptake of the 
local tumor vasculature where the drug is released. 
The microbubbles also may be conjugated to ligands 
that target tumors. Microbubbles targeted to integrins 
commonly found on tumor neovasculature have 
already been developed for molecular imaging of 
tumors [45] and may be used to enhance selective 
delivery of therapy to tumors. Lastly, microbubbles 
are useful for monitoring the response to anticancer 
therapies affecting tumor perfusion as they enhance 
within the tumor microvasculature [23, 30]. Aside 
from being ultrasound contrast agents, conjugation of 
nanoparticles or liposomes with super paramagnetic 
iron oxide (SPIO) particles or gadolinium conjugates 
could also enhance imaging sensitivity by other 
modalities such as magnetic resonance imaging. 
Limitations to this study and concerns for AVUS 
exist and should be further investigated. First, this 
study focuses on the immediate effects of AVUS on 
HCC, within the first two hours of therapy. While this 
immediate effect is useful in understanding the effect 
AVUS has on the tumor vasculature and perfusion, 
further studies of the bioeffects over time will inform 
whether the therapy contributes to a response and 
regression of HCC. This should look at delayed time 
points allowing for necrosis and other biological 
responses including the previously noted immune 
response [10] to manifest and ideally include survival 
studies. Additionally, surrounding organs and liver 
tissue should also be carefully assessed at this 
timepoint to assess for safety. Secondly, the two 
dosages tested changed multiple parameters at once, 
including ultrasound power and frequency, time of 
administration, and microbubble concentration. 
Further investigation of which parameters are most 
influential in the varying effects of AVUS and the 
point at which perfusion effects transition from an 
increase to disruption are necessary to achieve these 
effects in larger animals or humans. Lastly, the pulse 
sequences delivered can be optimized to enhance 
therapy and penetration of acoustic energy into the 
central part of tumor. Although the current 
therapeutic protocol involving  intermittent 
insonations allows for damage to the outer vessels in 
the early treatment to allow increased penetration of 
US in the latter part of the treatment, a more elegant 
approach of interleaving flash replenishment 
sequences to the treatment to enhance ultrasound 
penetration may provide significant improvement in 
the treatment response and also reduce variability.  
 In conclusion, this study was able to translate 
AVUS into a realistic model of HCC, evaluating the 
feasibility of affecting authentic tumor vascular in 
situ. We found the AVUS induced significant vascular 
changes. A reduced dose was found to be ineffective 
at disrupting blood flow but could possibly have 
potential for enhancing blood flow. Further studies of 
the long-term effect and benefit of AVUS in HCC will 
inform its potential for further translation and 
implementation as a noninvasive locoregional 
therapy for HCC.   
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